Therapeutic Asset Ratings

228 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
t3011 Lymphoma	ImmVira Pharma Co. Ltd	P1/2	CC (41)
Valemetostat Lymphoma	M.D. Anderson Cancer Center	P1/2	CC (41)
zg005 Lymphoma	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	P1/2	CC (41)
Γδ T Cells Lymphoma	Chinese PLA General Hospital	P1/2	CC (41)
dz-002 Lymphoma	Da Zen Theranostics Inc	P1	CC (40)
hlx26 Lymphoma	Shanghai Henlius Biotech	P1	CC (40)
ASTX 660 Lymphoma	Taiho Oncology, Inc.	P1/2	C (39)
Vic-1911 Lymphoma	Masonic Cancer Center, University of Minnesota	P1/2	C (39)
19ucart Lymphoma	YANRU WANG	P1	C (37)
Anti-Cd30 Bispecific Antibody-Armed Anti-Cd3-Activated Autologous T-Cells Lymphoma	Medical College of Wisconsin	P1	C (37)
Atlcar.Cd30.Ccr4 Cells Lymphoma	UNC Lineberger Comprehensive Cancer Center	P1	C (37)
BMS-986403 Lymphoma	Bristol-Myers Squibb	P1	C (37)
Bpi-371153 Lymphoma	Betta Pharmaceuticals Co., Ltd.	P1	C (37)
BYON4228 Lymphoma	Byondis B.V.	P1	C (37)
can2109 Lymphoma	Canwell Biotech Limited	P1	C (37)
cd19/baff-r in vivo car-t cell intravenous infusion Lymphoma	Qi deng	P1	C (37)
cd19/cd22-bispecific car-t cells Lymphoma	Seattle Children's Hospital	P1	C (37)
cd22 car-t Lymphoma	Seattle Children's Hospital	P1	C (37)
cs08399 Lymphoma	Chipscreen Biosciences, Ltd.	P1	C (37)
DOTATOC Lymphoma	ITM Solucin GmbH	P1	C (37)
FLUOROGLUTAMINE (2S,4R) Lymphoma	Memorial Sloan Kettering Cancer Center	P1	C (37)
Former Process Shr2554 、New Process Shr2554 Lymphoma	Jiangsu HengRui Medicine Co., Ltd.	P1	C (37)
Gamitrinib Lymphoma	Fox Chase Cancer Center	P1	C (37)
Grc 54276 Lymphoma	Glenmark Specialty S.A.	P1	C (37)
hg146 Lymphoma	HitGen Inc.	P1	C (37)

Showing 176 to 200 of 228 assets